Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors

被引：142

作者：

Cives, M. ^{[1
]}

Ghayouri, M. ^{[1
]}

Morse, B. ^{[1
]}

Brelsford, M. ^{[1
]}

Black, M. ^{[1
]}

Rizzo, A. ^{[2
]}

Meeker, A. ^{[2
]}

Strosberg, J. ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA

[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

来源：

关键词：

predictive factors; MGMT; ALT; DAXX; ATRX; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROTEIN EXPRESSION; TEMOZOLOMIDE; MGMT; GLIOBLASTOMA; CAPECITABINE; ASSOCIATION; INSTABILITY; GUIDELINES; NEOPLASMS;

D O I：

10.1530/ERC-16-0147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%. Small retrospective studies suggest that O-6-methylguanine DNA methyltransferase (MGMT) deficiency predicts response to temozolomide. High tumor proliferative activity is also commonly perceived as a significant predictor of response to cytotoxic chemotherapy. It is unclear whether chromosomal instability (CIN), which correlates with alternative lengthening of telomeres (ALT), is a predictive factor. In this study, we evaluated 143 patients with advanced pNET who underwent treatment with CAPTEM for radiographic and biochemical response. MGMT expression (n = 52), grade (n = 128) and ALT activation (n = 46) were investigated as potential predictive biomarkers. Treatment with CAPTEM was associated with an overall response rate (ORR) of 54% by RECIST 1.1. Response to CAPTEM was not influenced by MGMT expression, proliferative activity or ALT pathway activation. Based on these results, no biomarker-driven selection criteria for use of the CAPTEM regimen can be recommended at this time.

引用

页码：759 / 767

页数：9

共 23 条

[1] ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].

ALLRED, DC ;

CLARK, GM ;

ELLEDGE, R ;

FUQUA, SAW ;

BROWN, RW ;

CHAMNESS, GC ;

OSBORNE, CK ;

MCGUIRE, WL .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206

[2] Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors [J].

Chan, Jennifer A. ;

Stuart, Keith ;

Earle, Craig C. ;

Clark, Jeffrey W. ;

Bhargava, Pankaj ;

Miksad, Rebecca ;

Blaszkowsky, Lawrence ;

Enzinger, Peter C. ;

Meyerhardt, Jeffrey A. ;

Zheng, Hui ;

Fuchs, Charles S. ;

Kulke, Matthew H. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (24) :2963-2968

[3] Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide [J].

Chinot, Olivier L. ;

Barrie, Maryline ;

Fuentes, Stephane ;

Eudes, Nathalie ;

Lancelot, Sophie ;

Metellus, Philippe ;

Muracciole, Xavier ;

Braguer, Diane ;

Ouafik, L'Houcine ;

Martin, Pierre-Marie ;

Dufour, Henry ;

Figarella-Branger, Dominique .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1470-1475

[4]

Cives M, 2014, ONCOLOGY-NY, V28, P749

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6] Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors [J].

Ekeblad, Sara ;

Sundin, Anders ;

Janson, Eva Tiensuu ;

Welin, Staffan ;

Granberg, Dan ;

Kindmark, Henrik ;

Dunder, Kristina ;

Kozlovacki, Gordana ;

Orlefors, Hakan ;

Sigurd, Mattias ;

Oberg, Kjell ;

Eriksson, Barbro ;

Skogseid, Britt .

CLINICAL CANCER RESEARCH, 2007, 13 (10) :2986-2991

[7] ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors [J].

Falconi, Massimo ;

Bartsch, Detlef Klaus ;

Eriksson, Barbro ;

Kloeppel, Guenter ;

Lopes, Jose M. ;

O'Connor, Juan M. ;

Salazar, Ramon ;

Taal, Babs G. ;

Vullierme, Marie Pierre ;

O'Toole, Dermot .

NEUROENDOCRINOLOGY, 2012, 95 (02) :120-134

[8] Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience [J].

Fine, Robert L. ;

Gulati, Anthony P. ;

Krantz, Benjamin A. ;

Moss, Rebecca A. ;

Schreibman, Stephen ;

Tsushima, Dawn A. ;

Mowatt, Kelley B. ;

Dinnen, Richard D. ;

Mao, Yuehua ;

Stevens, Peter D. ;

Schrope, Beth ;

Allendorf, John ;

Lee, James A. ;

Sherman, William H. ;

Chabot, John A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) :663-670

[9] MGMT: Its role in cancer aetiology and cancer therapeutics [J].

Gerson, SL .

NATURE REVIEWS CANCER, 2004, 4 (04) :296-307

[10] Altered Telomeres in Tumors with ATRX and DAXX Mutations [J].

Heaphy, Christopher M. ;

de Wilde, Roeland F. ;

Jiao, Yuchen ;

Klein, Alison P. ;

Edil, Barish H. ;

Shi, Chanjuan ;

Bettegowda, Chetan ;

Rodriguez, Fausto J. ;

Eberhart, Charles G. ;

Hebbar, Sachidanand ;

Offerhaus, G. Johan ;

McLendon, Roger ;

Rasheed, B. Ahmed ;

He, Yiping ;

Yan, Hai ;

Bigner, Darell D. ;

Oba-Shinjo, Sueli Mieko ;

Marie, Suely Kazue Nagahashi ;

Riggins, Gregory J. ;

Kinzler, Kenneth W. ;

Vogelstein, Bert ;

Hruban, Ralph H. ;

Maitra, Anirban ;

Papadopoulos, Nickolas ;

Meeker, Alan K. .

SCIENCE, 2011, 333 (6041) :425-425

← 1 2 3 →